Management of relapse in naltrexone maintenance for heroin dependence

Drug and Alcohol Dependence

Volumn 91, Issue 2-3, 2007, Pages 289-292

  Sullivan, Maria A ^a   Garawi, Fatima ^a   Bisaga, Adam ^a   Comer, Sandra D ^a   Carpenter, Kenneth ^a   Raby, Wilfrid N ^a   Anen, Stephen J ^a   Brooks, Adam C ^b   Jiang, Huiping ^a   Akerele, Evaristo ^c   Nunes, Edward V ^a  

^a New York State Psychiatric Institute ^*  (United States)

^b TREATMENT RESEARCH INSTITUTE   (United States)

^c HARLEM HOSPITAL CENTER   (United States)

Author keywords

Heroin; Naltrexone; Opioid; Relapse; Treatment

Indexed keywords

DIAMORPHINE; NALTREXONE; RIBOFLAVIN;

ABSTINENCE; ARTICLE; CLINICAL TRIAL; DETOXIFICATION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG DEPENDENCE; DRUG USE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADULT; BEHAVIOR THERAPY; COMBINED MODALITY THERAPY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; FEMALE; FOLLOW-UP STUDIES; HEROIN DEPENDENCE; HUMANS; INPATIENTS; MALE; MIDDLE AGED; NALTREXONE; NARCOTIC ANTAGONISTS; OUTPATIENTS; RECURRENCE; TIME FACTORS;

EID: 35148898223     PISSN: 03768716     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2007.06.013     Document Type: Article

References (18)

1. Anton R.F., O'Malley S.S., Ciraulo D.A., Cisler R.A., Couper D., Donovan D.M., Gastfriend D.R., Hosking J.D., Johnson B.A., LoCastro J.S., Longabaugh R., Mason B.J., Mattson M.E., Miller W.R., Pettinati H.M., Randall C.L., Swift R., Weiss R.D., Williams L.D., Zweben A., and COMBINE Study Research Group. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA 295 17 (2006) 2003-2017
2. Carroll K.M., Ball S.A., Nich C., O'Connor P.G., Eagan D.A., Frankforter T.L., Triffleman E.G., Shi J., and Rounsaville B.J. Targeting behavioral therapies to enhance naltrexone treatment of opioid dependence: efficacy of contingency management and significant other involvement. Arch. Gen. Psychiatr. 58 8 (2001) 755-761
3. Comer S.D., Sullivan M.A., Yu E., Rothenberg J.L., Kleber H.D., Kampman K., Dackis C., and O'Brien C.P. Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial. Arch. Gen. Psychiatr. 63 2 (2006) 210-218
4. Cornish J.W., Metzger D., Woody G.E., Wilson D., McLellan A.T., Vandergrift B., and O'Brien C.P. Naltrexone pharmacotherapy for opioid dependent federal probationers. J. Subst. Abuse Treat. 14 (1997) 529-534
5. Fals-Stewart W., and O'Farrell T.J. Behavioral family counseling and naltrexone for male opioid-dependent patients. J. Consult. Clin. Psychol. 71 3 (2003) 432-442
6. Hulse G.K., Tait R.J., Comer S.D., Sullivan M.A., Jacobs I.G., and Arnold-Reed D. Reducing hospital presentations for opioid overdose in patients treated with sustained release naltrexone implants. Drug Alcohol Depend. 79 3 (2005) 351-357
7. Miotto K., McCann M.J., Rawson R.A., Frosch D., and Ling W. Overdose, suicide attempts and death among a cohort of naltrexone-treated opioid addicts. Drug Alcohol Depend. 45 1-2 (1997) 131-134
8. Nunes E.V., Rothenberg J.L., Sullivan M.A., Carpenter K.M., and Kleber H.D. Behavioral therapy to augment oral naltrexone for opioid dependence: a ceiling on effectiveness. Am. J. Drug Alcohol Abuse. 32 4 (2006) 503-517
9. Oslin D.W., Pettinati H.M., Volpicelli J.R., Wolf A.L., Kampman K.M., and O'Brien C.P. The effects of naltrexone on alcohol and cocaine use in dually addicted patients. J. Subst. Abuse Treat. 16 (1999) 163-167
10. Preston K.L., Silverman K., Umbricht A., DeJesus A., Montoya I.D., and Schuster C.R. Improvement in naltrexone treatment compliance with contingency management. Drug Alcohol Depend. 54 2 (1999) 127-135
11. Ritter A.J. Naltrexone in the treatment of heroin dependence: relationship with depression and risk of overdose. Aust. N.Z. J. Psychiatr. 36 2 (2002) 224-228
12. Rothenberg J.L., Sullivan M.A., Church S.H., Seracini A., Collins E., Kleber H.D., and Nunes E.V. Behavioral naltrexone therapy: an integrated treatment for opiate dependence. J. Subst. Abuse Treat. 23 4 (2002) 351-360
13. Schmitz J.M., Stotts A.L., Rhoades H.M., and Grabowski J. Naltrexone and relapse treatment for cocaine-dependent patients. Addict. Behav. 26 (2001) 167-180
14. Sullivan M.A., Rothenberg J.L., Vosburg S.K., Church S.H., Feldman S.J., Epstein E.M., Kleber H.D., and Nunes E.V. Predictors of retention in naltrexone maintenance for opioid dependence: analysis of a stage I trial. Am. J. Addict. 15 2 (2006) 150-159
15. Sullivan M.A., Vosburg S.K., and Comer S.D. Depot naltrexone: antagonism of the reinforcing, subjective, and physiological effects of heroin. Psychopharmacology 189 1 (2006) 37-46
16. Waal H., Frogopsahl G., Olsen L., Christophersen A.S., and Morland J. Naltrexone implants-duration, tolerability and clinical usefulness. A pilot study. Eur. Addict. Res. 12 3 (2006) 138-144
17. Washton A.M., Gold M.S., and Pottash A.C. Successful use of naltrexone in addicted physicians and business executives. Adv. Alcohol Subst. Abuse 4 2 (1984) 89-96
18. White J.M., and Irvine R.J. Mechanisms of fatal opioid overdose. Addiction 94 7 (1999) 961-972